<DOC>
	<DOCNO>NCT02303951</DOCNO>
	<brief_summary>Evaluation efficacy , safety biologic effect neo-adjuvant treatment vemurafenib + cobimetinib patient limited metastasis melanoma stage IIIC/IV melanoma .</brief_summary>
	<brief_title>Neoadjuvant Vemurafenib + Cobimetinib Melanoma : NEO-VC</brief_title>
	<detailed_description>Patients hardly resectable/unresectable limited metastasis malignant melanoma stage IIIC/IV ( AJCC 2010 ) carry BRAF V600 mutation , order achieve operability enrol NEO-VC-study . The main aim study achieve operability high percentage patient neoadjuvant treatment shrinkage tumor . Patients operable stage IV disease show impressive survival benefit long term ( 5 . ) survival rate around 30 % . Only percentage 20 % presently treat complete metastasectomy . This percentage may enlarge pre-treatment efficacious antitumor drug .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult patient , ≥ 18 year age Willing able give inform consent Metastatic melanoma , stage IIIC IV ( American Joint Committee Cancer 2010 ) ECOG ( Eastern Cooperative Oncology Group ) : 01 MAPkinase pathway inhibitor treatmentnaïve Positive BRAF V600 mutation , preferentially show metastatic tumor tissue Decision eligibility neoadjuvant combine vemurafenib cobimetinib treatment interdisciplinary tumor board . Patient limit number metastasis organ system involve select , make surgical resection neoadjuvant treatment probable . Measurable disease Response Evaluation Criteria In Solid Tumors ( RECIST V1.1 ) criteria Adequate hematologic organ function define : ANC ( absolute neutrophil count ) ≥ 1.5 × 109/L Platelets ≥ 100 × 109/L Hemoglobin ≥ 9 g/dL Albumin ≥ 2.5 g/dL Bilirubin ≤ 1.5 × upper limit normal ( ULN ) AST ( aspartate aminotransferase ) , ALT ( alanine aminotransferase ) , alkaline phosphatase ≤ 3 × ULN , except patient document liver metastasis : AST and/or ALT ≤ 5 × ULN Patients document liver bone metastasis : alkaline phosphatase ≤ 5 × ULN Serum creatinine ≤ 1.5 × ULN For fertile men : effective contraception treatment 6 month completion manner risk pregnancy minimize For woman childbearing potential , negative pregnancy test perform within 28 day prior study enrolment Candidates direct surgery : patient single site easily resectable metastasis Major surgical procedure significant traumatic injury within 2 week prior first dose study drug treatment Active central nervous system metastases except metastasis complete resection stereotactic irradiation stable status least 3 month History carcinomatous meningitis Severe cardiovascular disease within 6 month prior study drug administration History evidence cardiovascular risk include follow LVEF ( leave ventricular ejection fraction ) &lt; 50 % &lt; LLN ( low limit normal ) , whichever low QTc ( correct QT interval ) interval &gt; 450 ms evidence clinically significant uncontrolled arrhythmias History evidence retinal vein occlusion Previous malignancy within 5 year prior study , except basal squamous cell carcinoma skin , melanoma insitu , carcinoma insitu cervix Psychological , familial , sociological , geographical condition permit compliance protocol Any condition unstable could jeopardize safety patient compliance study Legal incapacity limit legal capacity Subjects house institution official legal order Participation another clinical study experimental therapy within 30 day start treatment Pregnancy lactation period Concomitant use study therapy drug potential QT prolongation ( see database www.qtdrugs.org ) Known immediate delay hypersensitivity reaction idiosyncrasy cobimetinib and/or vemurafenib and/or excipients Patients disease affect liver function , viral hepatitis Patients receive medication know increase risk peripheral edema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>